NeuClone welcomes all strategic partnering opportunities regarding biosimilar development and product commercialisation.
Our products emphasise quality, affordability and scale. We believe that effective collaborations will help achieve our vision of improving access to life saving and life extending therapies across the world.
NeuClone welcomes all strategic partnering opportunities regarding biosimilar development and product commercialisation.
Our products emphasise quality, affordability and scale. We believe that effective collaborations will help achieve our vision of improving access to life saving and life extending therapies across the world.
NeuClone ensures the highest product quality standards from the outset. Through continual scrutiny, we maximise biosimilar attributes to deliver the best possible biosimilars and clinical outcomes for patients.
Since inception, NeuClone has focused on discovering and developing core antibody production technology to decrease the cost of manufacture. Our NeuMAX® technology, based on proprietary processes and IP, provides an integrated platform which enables major manufacturing advantages including cost and time productivity.
NeuClone holds a firm belief that current global markets and patient needs are drastically underserved when it comes to life-enhancing biologic therapies. Originator companies often sell their product to only a fraction of patients clinically eligible for drug treatment. To fulfil the unmet clinical needs of patients across the world, more drugs, of appropriate quality and lower price, must be made. This will not only improve patient access across diverse and very different economies and reimbursement systems, but also allow growth of sustainable business in the supply and marketing chain.